GoKawiilModerna-Merck mRNA vaccine cuts melanoma recurrence risk by 42% in trial
A phase III trial of 1,137 melanoma patients found that intismeran, a personalized mRNA vaccine developed by Moderna and Merck, reduced the risk of cancer recurrence or death by 42% when given alongside an immunotherapy drug after tumour-removal surgery. The companies released key results early after trial data leaked online ahead of their scheduled presentation at a European oncology conference in Madrid on 24 October.
GoKawiil's interpretation of the reporting above, not reported fact.
Researchers quoted in coverage describe a 42% risk reduction as unusually large compared with the roughly 10% improvements oncologists typically consider meaningful, suggesting the vaccine could become a significant addition to melanoma treatment if approved. Moderna's stock fell about 25% after the leak, which one analyst attributed to inflated market expectations rather than disappointing efficacy data, highlighting how investor sentiment can diverge from clinical significance.
- Intismeran, made by Moderna and Merck, cut melanoma recurrence or death risk by 42% combined with immunotherapy.
- The trial included 1,137 patients with moderate to advanced melanoma across 157 centres.
- Moderna's share price dropped ~25% after trial data leaked before the official presentation.
Source: nature.com — Basu, 2026-10-23
Published there as: “Moderna mRNA vaccine almost halves the risk of skin cancer returning”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.